Voyager Therapeutics (VYGR) Competitors

Voyager Therapeutics (NASDAQ:VYGR) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

Is VYGR or AMLX more profitable?

Amylyx Pharmaceuticals has a net margin of 0.00% compared to Voyager Therapeutics' net margin of -253.49%. Voyager Therapeutics' return on equity of -37.65% beat Amylyx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Voyager Therapeutics	-253.49%	-37.65%	-28.89%
Amylyx Pharmaceuticals	N/A	-82.48%	-70.15%

Which has preferable valuation & earnings, VYGR or AMLX?

Voyager Therapeutics has higher earnings, but lower revenue than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Voyager Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Voyager Therapeutics	$80M	2.53	-$65M	-$1.85	-1.97
Amylyx Pharmaceuticals	$87.37M	8.47	-$301.74M	-$2.50	-3.32

Do analysts recommend VYGR or AMLX?

Voyager Therapeutics currently has a consensus target price of $13.25, indicating a potential upside of 262.94%. Amylyx Pharmaceuticals has a consensus target price of $11.75, indicating a potential upside of 41.57%. Given Voyager Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Voyager Therapeutics is more favorable than Amylyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Voyager Therapeutics	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.13
Amylyx Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00

Do institutionals and insiders believe in VYGR or AMLX?

48.0% of Voyager Therapeutics shares are held by institutional investors. Comparatively, 95.8% of Amylyx Pharmaceuticals shares are held by institutional investors. 6.4% of Voyager Therapeutics shares are held by company insiders. Comparatively, 12.3% of Amylyx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Does the media prefer VYGR or AMLX?

In the previous week, Voyager Therapeutics had 5 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 14 mentions for Voyager Therapeutics and 9 mentions for Amylyx Pharmaceuticals. Amylyx Pharmaceuticals' average media sentiment score of 0.16 beat Voyager Therapeutics' score of -0.33 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Voyager Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Amylyx Pharmaceuticals	1 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has more risk & volatility, VYGR or AMLX?

Voyager Therapeutics has a beta of 0.9, indicating that its stock price is 10% less volatile than the S&P 500. Comparatively, Amylyx Pharmaceuticals has a beta of -0.46, indicating that its stock price is 146% less volatile than the S&P 500.

Summary

Voyager Therapeutics beats Amylyx Pharmaceuticals on 9 of the 17 factors compared between the two stocks.